Antares Pharma and Boston Scientific Look to Make Headway in Surging Medical Supplies Industry
22 March 2012 - 11:20PM
Marketwired
Medical device and technology stocks have performed admirably in
2012. Year to date, the iShares Dow Jones U.S. Medical Devices
Index Fund is up more than 15 percent. While investor sentiment
appears positive at the moment, politicians and consumers are
calling for greater oversight into the industry. Moreover, a
medical device tax, which became law nearly 2 years ago as part of
the Patient Protection & Affordable Care Act, is set to go into
effect on January 1, 2013. The Paragon Report examines the outlook
for companies in the Medical Equipment & Supplies industry and
provides equity research on Antares Pharma Inc. (NYSE Amex: AIS)
and Boston Scientific Corporation (NYSE: BSX). Access to the full
company reports can be found at: www.paragonreport.com/AIS
www.paragonreport.com/BSX
A recent Consumer Reports poll shows overwhelming public support
for strong medical device safety oversight. The poll was released
as House and Senate Committees have issued draft legislation to
reauthorize the statute governing medical devices and at a time
when the FDA's process for reviewing new implants has come under
increased criticism. The House Energy and Commerce Health
Subcommittee's draft bill would weaken device safety oversight and
should be rejected by Congress, according to Consumers Union, the
policy and advocacy arm of Consumer Reports.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the Medical Equipment & Supplies
industry register with us free at www.paragonreport.com and get
exclusive access to our numerous stock reports and industry
newsletters.
Most medical devices don't require proof that they have been
clinically tested and found to be safe and effective before they
are cleared for distribution or sale by the Food and Drug
Administration.
While much of the House calls for less oversight, a bipartisan
foursome has crafted a Senate bill that would arm the FDA for
stronger oversight of medical devices while also pushing it into
action. The legislation would require the agency to issue a final
Unique Device Identifier (UDI) rule by the end of 2012 and add
medical devices to the FDA's Sentinel postmarket surveillance
initiative.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Vistashares Artificial I... (AMEX:AIS)
Historical Stock Chart
From Dec 2024 to Jan 2025
Vistashares Artificial I... (AMEX:AIS)
Historical Stock Chart
From Jan 2024 to Jan 2025
Real-Time news about Vistashares Artificial Intelligence Supercycle ETF (American Stock Exchange): 0 recent articles
More Paragon Financial Limited News Articles